Denise Scots-Knight net worth and biography

Denise Scots-Knight Biography and Net Worth

Denise is CEO, a board member and co-founder of Mereo. Denise has over 25 years’ experience in the biopharmaceutical industry in R&D management and venture capital.

She was in R&D management at Amersham and Fisons and a senior executive at Scientific Generics before joining Rothschild Asset Management as an investment manager. In 1999 she joined Nomura and was a Managing Director leading the life science investments in biotechnology companies. She led the Phase4 Partners MBO from Nomura in 2010.

Denise had served on many US and European private and public boards. She is currently a board member of Elanco Animal Health Inc. Denise has a PhD and BSc (Hons) from Birmingham University and was a Fulbright scholar at UC Berkeley.

What is Denise Scots-Knight's net worth?: The estimated net worth of Denise Scots-Knight is at least $1.77 million as of September 12th, 2024. Scots-Knight owns 868,967 shares of Mereo BioPharma Group stock worth more than $1,772,693 as of December 5th. This net worth estimate does not reflect any other assets that Scots-Knight may own. Additionally, Scots-Knight receives a salary of $890,560.00 as CEO at Mereo BioPharma Group. Learn More about Denise Scots-Knight's net worth.
How old is Denise Scots-Knight?: Scots-Knight is currently 65 years old. There are 7 older executives and no younger executives at Mereo BioPharma Group. Learn More on Denise Scots-Knight's age.
What is Denise Scots-Knight's salary?: As the CEO of Mereo BioPharma Group plc - Sponsored ADR, Scots-Knight earns $890,560.00 per year. Learn More on Denise Scots-Knight's salary.
How do I contact Denise Scots-Knight?: The corporate mailing address for Scots-Knight and other Mereo BioPharma Group executives is ONE CAVENDISH PLACE FOURTH FLOOR, LONDON X0, W1G0QF. Mereo BioPharma Group can also be reached via phone at 44-33-3023-7300 and via email at [email protected]. Learn More on Denise Scots-Knight's contact information.
Has Denise Scots-Knight been buying or selling shares of Mereo BioPharma Group?: Denise Scots-Knight has not been actively trading shares of Mereo BioPharma Group during the past quarter. Most recently, Denise Scots-Knight sold 28,611 shares of the business's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $4.47, for a transaction totalling $127,891.17. Following the completion of the sale, the chief executive officer now directly owns 868,967 shares of the company's stock, valued at $3,884,282.49. Learn More on Denise Scots-Knight's trading history.
Who are Mereo BioPharma Group's active insiders?: Mereo BioPharma Group's insider roster includes Christine Fox (CFO), Alexandra Hughes-Wilson (Insider), John Lewicki (Insider), Deepika Pakianathan (Director), Denise Scots-Knight (CEO), and Charles Sermon (General Counsel). Learn More on Mereo BioPharma Group's active insiders.

Denise Scots-Knight Insider Trading History at Mereo BioPharma Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/12/2024	Sell	28,611	$4.47	$127,891.17	868,967
6/25/2024	Sell	40,712	$3.69	$150,227.28	801,791

Denise Scots-Knight Buying and Selling Activity at Mereo BioPharma Group

Mereo BioPharma Group Company Overview

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Today's Range

Now: $2.04

$1.90

$2.06

50 Day Range

MA: $1.92

$1.75

$2.24

2 Week Range

Now: $2.04

$1.47

$3.94

Volume

2,428,717 shs

Average Volume

1,837,555 shs

Market Capitalization

$324.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.44

Denise Scots-Knight Biography and Net Worth

What is Denise Scots-Knight's net worth?

How old is Denise Scots-Knight?

What is Denise Scots-Knight's salary?

How do I contact Denise Scots-Knight?

Has Denise Scots-Knight been buying or selling shares of Mereo BioPharma Group?

Who are Mereo BioPharma Group's active insiders?